Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 20073992 | HLA-C (HLA-C) | lipodystrophy | NA | stavudine | NA | unclassified | |
| the clinical characteristics and allelic distribution of hla-a, hla-b, hla-c, hla-drb1, hla-dqb1, and hla-dpb1 were compared between the case group and the control group, to determine the possible association with stavudine-associated lipodystrophy. | |||||||
| 20073992 | HLA-DQB1 (HLA-DQB1) | lipodystrophy | NA | stavudine | NA | unclassified | |
| the clinical characteristics and allelic distribution of hla-a, hla-b, hla-c, hla-drb1, hla-dqb1, and hla-dpb1 were compared between the case group and the control group, to determine the possible association with stavudine-associated lipodystrophy. | |||||||
| 20073992 | HLA-B (HLA-B) | lipodystrophy | NA | stavudine | NA | unclassified | |
| the clinical characteristics and allelic distribution of hla-a, hla-b, hla-c, hla-drb1, hla-dqb1, and hla-dpb1 were compared between the case group and the control group, to determine the possible association with stavudine-associated lipodystrophy. | |||||||
| 20073992 | HLA-DRB1 (HLA-DRB1) | lipodystrophy | NA | stavudine | NA | unclassified | |
| the clinical characteristics and allelic distribution of hla-a, hla-b, hla-c, hla-drb1, hla-dqb1, and hla-dpb1 were compared between the case group and the control group, to determine the possible association with stavudine-associated lipodystrophy. | |||||||
| 20073992 | HLA-B*40 | lipodystrophy | NA | stavudine | NA | unclassified | |
| by use of forward stepwise logistic regression, the presence of hla-b*4001 (odds ratio [or], 14.05; 95% confidence interval [ci], 2.57-76.59; p=.002) and a longer duration of stavudine treatment (or, 1.02; 95% ci, 1.00-1.04; p=.02) were significantly associated with stavudine-associated lipodystrophy, whereas a higher body mass index during treatment (or, 0.73; 95% ci, 0.61-0.86; p<.001) was associated with a lower risk for lipodystrophy. | |||||||
| 20073992 | HLA-B*40 | lipodystrophy | NA | stavudine | NA | positive | |
| hla-b*4001 has a high specificity (95.8%) and a positive predictive value (88.9%) for lipodystrophy. | |||||||
| 20073992 | HLA-B*40 | lipodystrophy | NA | stavudine | NA | unclassified | |
| hla-b*4001 is a strong genetic risk factor for stavudine-associated lipodystrophy in hiv-infected patients in thailand. | |||||||
| 20073992 | HLA-B*40 | lipodystrophy | NA | stavudine | NA | unclassified | |
| hla-b*4001 may be used as a genetic marker to predict which patients will develop stavudine-associated lipodystrophy, to avoid or shorten the duration of stavudine use. | |||||||
| 25361850 | HLA-B*35 | lamivudine | NA | nevirapine | NA | unclassified | |
| NA | |||||||
| 25361850 | HLA-B*35 | lamivudine | NA | nevirapine | NA | unclassified | |
| NA | |||||||
Copyright 2024